Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.49) by 112.98 percent. This is a 275 percent decrease over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $15.165 million which beat the analyst consensus estimate of $12.174 million by 24.57 percent. This is a 6.51 percent decrease over sales of $16.221 million the same period last year.